CONCENTRATION-RESPONSE RELATIONSHIP IN IMIPRAMINE TREATMENT OF DIABETIC NEUROPATHY SYMPTOMS

被引:79
作者
SINDRUP, SH
GRAM, LF
SKJOLD, T
FROLAND, A
BECKNIELSEN, H
机构
[1] ODENSE UNIV HOSP,DEPT INTERNAL MED,DK-5000 ODENSE,DENMARK
[2] FREDERICIA CTY HOSP,DEPT INTERNAL MED,FREDERICIA,DENMARK
关键词
D O I
10.1038/clpt.1990.65
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A single-blind imipramine dose titration study was conducted in 15 diabetic patients with neuropathy symptoms. The effect of treatment was evaluated by use of visual analog scales. Imipramine doses were individually adjusted until doses yielded plasma concentrations of imipramine plus desipramine that were well above 400 nmol/L or until all neuropathy symptoms had vanished. In all except one patient, there was marked relief of symptoms. In the responding patients (n = 14), much of the effect occurred at plasma levels of imipramine plus desipramine below 100 nmol/L, but a considerable interindividual variation was observed. Concentrations above 400 to 500 nmol/L were required to ensure maximal effect in all patients, and we did not find any indication of a decreased effect at high drug levels. The dose-dependent kinetics of imipramine was confirmed, and dose increments should therefore be carried out in small steps and preferably with monitoring of drug levels. © 1990.
引用
收藏
页码:509 / 515
页数:7
相关论文
共 18 条
  • [1] DOSE-DEPENDENT KINETICS OF IMIPRAMINE IN ELDERLY PATIENTS
    BJERRE, M
    GRAM, LF
    KRAGHSORENSEN, P
    KRISTENSEN, CB
    PEDERSEN, OL
    MOLLER, M
    THAYSSEN, P
    [J]. PSYCHOPHARMACOLOGY, 1981, 75 (04) : 354 - 357
  • [2] CONTINUOUS SUBCUTANEOUS INSULIN INFUSION IN THE MANAGEMENT OF PAINFUL DIABETIC NEUROPATHY
    BOULTON, AJM
    DRURY, J
    CLARKE, B
    WARD, JD
    [J]. DIABETES CARE, 1982, 5 (04) : 386 - 390
  • [3] STEADY-STATE CONCENTRATIONS OF IMIPRAMINE AND ITS METABOLITES IN RELATION TO THE SPARTEINE DEBRISOQUINE POLYMORPHISM
    BROSEN, K
    KLYSNER, R
    GRAM, LF
    OTTON, SV
    BECH, P
    BERTILSSON, L
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 30 (06) : 679 - 684
  • [4] STEADY-STATE LEVELS OF IMIPRAMINE AND ITS METABOLITES - SIGNIFICANCE OF DOSE-DEPENDENT KINETICS
    BROSEN, K
    GRAM, LF
    KLYSNER, R
    BECH, P
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 30 (01) : 43 - 49
  • [5] NORTRIPTYLINE AND FLUPHENAZINE IN THE SYMPTOMATIC TREATMENT OF DIABETIC NEUROPATHY - A DOUBLE-BLIND CROSSOVER STUDY
    GOMEZPEREZ, FJ
    RULL, JA
    DIES, H
    RODRIGUEZRIVERA, JG
    GONZALEZBARRANCO, J
    LOZANOCASTANEDA, O
    [J]. PAIN, 1985, 23 (04) : 395 - 400
  • [6] IMIPRAMINE METABOLITES IN BLOOD OF PATIENTS DURING THERAPY AND AFTER OVERDOSE
    GRAM, LF
    BJERRE, M
    KRAGHSORENSEN, P
    KVINESDAL, B
    MOLIN, J
    PEDERSEN, OL
    REISBY, N
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1983, 33 (03) : 335 - 342
  • [7] PLASMA-CONCENTRATION AND CLINICAL EFFECT IN IMIPRAMINE TREATMENT OF CHILDHOOD ENURESIS
    JORGENSEN, OS
    LOBER, M
    CHRISTIANSEN, J
    GRAM, LF
    [J]. CLINICAL PHARMACOKINETICS, 1980, 5 (04) : 386 - 393
  • [8] SELF-INHIBITING ACTION OF NORTRIPTYLINES ANTIDEPRESSIVE EFFECT AT HIGH PLASMA-LEVELS - RANDOMIZED, DOUBLE-BLIND-STUDY CONTROLLED BY PLASMA CONCENTRATIONS IN PATIENTS WITH ENDOGENOUS-DEPRESSION
    KRAGHSORENSEN, P
    HANSEN, CE
    BAASTRUP, C
    HVIDBERG, EF
    [J]. PSYCHOPHARMACOLOGIA, 1976, 45 (03): : 305 - 312
  • [9] KRISTENSEN CB, 1982, ACTA PHARMACOL TOX, V50, P130
  • [10] IMIPRAMINE TREATMENT OF PAINFUL DIABETIC NEUROPATHY
    KVINESDAL, B
    MOLIN, J
    FROLAND, A
    GRAM, LF
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1984, 251 (13): : 1727 - 1730